“`html
AvicedaS AVD-104 Shows Promise in Geographic Atrophy Trial
Table of Contents
Initial data from a Phase 2b clinical trial suggest Aviceda’s AVD-104 may offer a favorable efficacy and safety profile for treating geographic atrophy (GA) associated with advanced age-related macular degeneration (AMD).updated as of December 19, 2025, 02:59:13 PST.
Understanding Geographic Atrophy and Current Treatments
Age-related macular degeneration (AMD) is a major cause of vision loss in people over 60. Geographic atrophy (GA) is the advanced “dry” form of AMD, characterized by the progressive degeneration of retinal cells in the macula, leading to irreversible central vision loss. Currently approved treatments, like avacincaptad pegol (Izervay) and pegcetacoplan (Syfovre), are complement inhibitors designed to slow the progression of GA, but they don’t cure it and require frequent injections.
According to the American Academy of Ophthalmology, approximately 1.5 million Americans have GA, and that number is expected to rise with the aging population.
Aviceda’s AVD-104: A New Approach
AVD-104 is a novel SIGLEC (Sialic acid-binding immunoglobulin-like lectin) inhibitor. SIGLECs are a family of proteins involved in immune regulation, and inhibiting them may help reduce inflammation and protect retinal cells. Aviceda Therapeutics is developing AVD-104 as a potential treatment for GA.
On December 15, 2025, Aviceda released initial data from its Phase 2b SIGLEC clinical trial evaluating AVD-104. The trial, a randomized, multi-center, double-masked, active comparator-controlled study, focused on the rate of change in GA area compared to monthly avacincaptad pegol. However, the data released initially only pertained to the AVD-104 arm of the trial, meaning a direct comparison to the control group is not yet available.
Initial Data Highlights
While a full comparison is pending, preliminary analysis of the AVD-104 arm data suggests a potentially favorable profile when compared to existing clinical trial data for pegcetacoplan and avacincaptad pegol. The company reports that patients receiving AVD-104 experienced a reduction in the rate of GA progression. The typical patient undergoing GA therapy with existing complement inhibitors still experiences a gradual loss of vision as the GA worsens, albeit at a slower rate than without treatment. The extent to which AVD-104 can mitigate this vision loss remains to be seen with the full data set.
Aviceda has not yet publicly released specific numerical data regarding the rate of change in GA area. Further details are expected upon full data publication and presentation at upcoming scientific conferences.
Safety Profile
The initial data also indicate a promising safety profile for AVD-104. The company reports that AVD-104 was generally well-
